Document is current
Any future updates will be listed below
-
Authors
Code, Jillianne
Sauer, Andrew J.
Mentz, Robert J.
Monroe, Rhonda E.
- License Information
-
More Information
Article History
Received: 22 July 2025
Accepted: 24 September 2025
First Online: 1 October 2025
Declarations
:
: This review was supported by Bayer AG, Berlin, Germany. The authors wrote the paper independently with the assistance of a medical writer, who was funded by the sponsor. The sponsor is also the manufacturer of finerenone. Jillianne Code declares no conflicts of interest. Andrew J. Sauer receives research funding support from: the Heart Failure Society of America (HFSA), AstraZeneca, Boehringer Ingelheim, Bayer, CSL Vifor, Pfizer, Rivus Pharmaceuticals, 35Pharma, Novo Nordisk, Edwards Lifesciences, and Story Health; consultant fees from: Abbott, Boston Scientific, Edwards Lifesciences, Impulse Dynamics, Acorai, General Prognostics, Story Health, Amgen, and Bayer; and holds stock ownership with: ISHI and Pulsli (both privately held digital health companies). Robert J. Mentz receives research support and honoraria from: Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim/Eli Lilly, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Medtronic, Merck, Novartis, Relypsa, Respicardia, Roche, Sanofi, Vifor, and Windtree Therapeutics. Rhonda E. Monroe receives honoraria from: 4Teen4, Abiomed, Medtronic, Merck, Novartis, and Roche.
